Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis

Indian Journal of Medical Research

Volumn 124, Issue DEC., 2006, Pages 689-696

  Shankar, S ^a   Grover, R ^a   Handa, Rohini ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti CCP 2; Anti cyclic citrullinated peptide antibodies; Erosions; Rheumatoid arthritis; Seronegative RA

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; PREVALENCE; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; AGED; BLOOD; CROSS-SECTIONAL STUDY; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 34247150260     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 1993; 13:131-4.
2. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumarol 1990; 17: 413-4.
3. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 1571-82.
4. Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979; 66: 377-84.
5. Van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis, results of a follow up study. J Rheumatol 1993; 20: 1288-96.
6. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in Rheumatoid arthritis. Arthritis Rheum 1986; 29: 494-500.
7. Vossenaar ER, Van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 107-11.
8. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273-81.
9. Van Gaalen FA, Linn Rasker SP, Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. A prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
10. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427-30.
11. Kroot EJ, de Jong BA, van Leeuwen MA Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-5.
12. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
13. Berglin E, padyukov I, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: 303-8.
14. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
15. Arnett FC, Edworthy SM, McShane DJ, Fries JF, Cooper NS, Healey LA, et al. The American Association revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996; 35: 1106-15.
17. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 611-6.
18. Gran JT. The epidemiology of rheumatoid arthritis. Monogr Allerg Immunol 1987; 21: 162-96.
19. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706-20.
20. Sharp JT. Scoring radiographic abnormalities in rheumatoid arthritis. J Rheumatol 1989; 16: 568-9.
21. Singer JM, Plotz CM. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. Am J Med 1956; 21: 888-92.
22. Zendman AJW, Van Venrooij WJ, Pruijn GJM. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatol 2006; 45: 20-5.
23. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by the presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA rheumatoid factor at disease onset. Ann Rheum Dis 2006; 65: 453-8.